nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—SLC29A1—Fludarabine—lymphatic system cancer	0.46	0.548	CbGbCtD
Dipyridamole—SLC29A1—Cytarabine—lymphatic system cancer	0.314	0.374	CbGbCtD
Dipyridamole—ABCC4—Methotrexate—lymphatic system cancer	0.0331	0.0394	CbGbCtD
Dipyridamole—ABCB1—Mitoxantrone—lymphatic system cancer	0.0154	0.0183	CbGbCtD
Dipyridamole—ABCB1—Vincristine—lymphatic system cancer	0.0106	0.0126	CbGbCtD
Dipyridamole—ABCB1—Methotrexate—lymphatic system cancer	0.00642	0.00764	CbGbCtD
Dipyridamole—PRUNE—Podofilox—Teniposide—lymphatic system cancer	0.00333	0.499	CbGdCrCtD
Dipyridamole—PRUNE—Vinorelbine—Vincristine—lymphatic system cancer	0.00198	0.297	CbGdCrCtD
Dipyridamole—PRUNE—Vinblastine—Vincristine—lymphatic system cancer	0.00136	0.204	CbGdCrCtD
Dipyridamole—Haemorrhage—Bleomycin—lymphatic system cancer	0.000498	0.00326	CcSEcCtD
Dipyridamole—Discomfort—Fludarabine—lymphatic system cancer	0.000497	0.00325	CcSEcCtD
Dipyridamole—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000496	0.00324	CcSEcCtD
Dipyridamole—Sweating increased—Mitoxantrone—lymphatic system cancer	0.000492	0.00322	CcSEcCtD
Dipyridamole—Dyspnoea—Teniposide—lymphatic system cancer	0.00049	0.0032	CcSEcCtD
Dipyridamole—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000483	0.00316	CcSEcCtD
Dipyridamole—Oedema—Fludarabine—lymphatic system cancer	0.000483	0.00316	CcSEcCtD
Dipyridamole—Vomiting—Mechlorethamine—lymphatic system cancer	0.000474	0.0031	CcSEcCtD
Dipyridamole—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000473	0.0031	CcSEcCtD
Dipyridamole—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000472	0.00309	CcSEcCtD
Dipyridamole—Rash—Mechlorethamine—lymphatic system cancer	0.00047	0.00307	CcSEcCtD
Dipyridamole—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000469	0.00307	CcSEcCtD
Dipyridamole—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000467	0.00305	CcSEcCtD
Dipyridamole—Flushing—Bleomycin—lymphatic system cancer	0.000462	0.00302	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000456	0.00298	CcSEcCtD
Dipyridamole—Myocardial infarction—Vincristine—lymphatic system cancer	0.000453	0.00296	CcSEcCtD
Dipyridamole—Feeling abnormal—Teniposide—lymphatic system cancer	0.000452	0.00296	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000449	0.00294	CcSEcCtD
Dipyridamole—Chills—Bleomycin—lymphatic system cancer	0.000447	0.00292	CcSEcCtD
Dipyridamole—Bone disorder—Methotrexate—lymphatic system cancer	0.000444	0.0029	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000444	0.0029	CcSEcCtD
Dipyridamole—Nausea—Mechlorethamine—lymphatic system cancer	0.000442	0.00289	CcSEcCtD
Dipyridamole—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000441	0.00289	CcSEcCtD
Dipyridamole—Alopecia—Bleomycin—lymphatic system cancer	0.00044	0.00288	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00044	0.00288	CcSEcCtD
Dipyridamole—Haemoglobin—Carmustine—lymphatic system cancer	0.000437	0.00286	CcSEcCtD
Dipyridamole—Urticaria—Teniposide—lymphatic system cancer	0.000436	0.00285	CcSEcCtD
Dipyridamole—Haemorrhage—Carmustine—lymphatic system cancer	0.000435	0.00284	CcSEcCtD
Dipyridamole—Abdominal pain—Teniposide—lymphatic system cancer	0.000434	0.00284	CcSEcCtD
Dipyridamole—Paraesthesia—Fludarabine—lymphatic system cancer	0.000433	0.00283	CcSEcCtD
Dipyridamole—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000433	0.00283	CcSEcCtD
Dipyridamole—Dyspnoea—Fludarabine—lymphatic system cancer	0.00043	0.00281	CcSEcCtD
Dipyridamole—Dyspepsia—Fludarabine—lymphatic system cancer	0.000425	0.00278	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000417	0.00273	CcSEcCtD
Dipyridamole—Fatigue—Fludarabine—lymphatic system cancer	0.000416	0.00272	CcSEcCtD
Dipyridamole—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000413	0.0027	CcSEcCtD
Dipyridamole—Pain—Fludarabine—lymphatic system cancer	0.000413	0.0027	CcSEcCtD
Dipyridamole—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000411	0.00269	CcSEcCtD
Dipyridamole—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000406	0.00266	CcSEcCtD
Dipyridamole—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000405	0.00265	CcSEcCtD
Dipyridamole—Hypersensitivity—Teniposide—lymphatic system cancer	0.000405	0.00265	CcSEcCtD
Dipyridamole—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000404	0.00264	CcSEcCtD
Dipyridamole—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000404	0.00264	CcSEcCtD
Dipyridamole—Flushing—Carmustine—lymphatic system cancer	0.000403	0.00264	CcSEcCtD
Dipyridamole—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000402	0.00263	CcSEcCtD
Dipyridamole—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000401	0.00262	CcSEcCtD
Dipyridamole—Anaemia—Bleomycin—lymphatic system cancer	0.000401	0.00262	CcSEcCtD
Dipyridamole—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000398	0.0026	CcSEcCtD
Dipyridamole—Asthenia—Teniposide—lymphatic system cancer	0.000394	0.00258	CcSEcCtD
Dipyridamole—Malaise—Bleomycin—lymphatic system cancer	0.000391	0.00256	CcSEcCtD
Dipyridamole—Pruritus—Teniposide—lymphatic system cancer	0.000388	0.00254	CcSEcCtD
Dipyridamole—Arrhythmia—Carmustine—lymphatic system cancer	0.000388	0.00254	CcSEcCtD
Dipyridamole—Cardiac disorder—Vincristine—lymphatic system cancer	0.000385	0.00252	CcSEcCtD
Dipyridamole—Alopecia—Carmustine—lymphatic system cancer	0.000384	0.00251	CcSEcCtD
Dipyridamole—Cough—Bleomycin—lymphatic system cancer	0.000378	0.00247	CcSEcCtD
Dipyridamole—Angiopathy—Vincristine—lymphatic system cancer	0.000377	0.00246	CcSEcCtD
Dipyridamole—Diarrhoea—Teniposide—lymphatic system cancer	0.000376	0.00246	CcSEcCtD
Dipyridamole—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000374	0.00245	CcSEcCtD
Dipyridamole—Chest pain—Bleomycin—lymphatic system cancer	0.000369	0.00241	CcSEcCtD
Dipyridamole—Myalgia—Bleomycin—lymphatic system cancer	0.000369	0.00241	CcSEcCtD
Dipyridamole—Alopecia—Vincristine—lymphatic system cancer	0.000367	0.0024	CcSEcCtD
Dipyridamole—Back pain—Carmustine—lymphatic system cancer	0.000366	0.00239	CcSEcCtD
Dipyridamole—Discomfort—Bleomycin—lymphatic system cancer	0.000365	0.00239	CcSEcCtD
Dipyridamole—Chills—Mitoxantrone—lymphatic system cancer	0.000363	0.00237	CcSEcCtD
Dipyridamole—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000361	0.00236	CcSEcCtD
Dipyridamole—Alopecia—Mitoxantrone—lymphatic system cancer	0.000357	0.00234	CcSEcCtD
Dipyridamole—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000357	0.00233	CcSEcCtD
Dipyridamole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000356	0.00233	CcSEcCtD
Dipyridamole—Tremor—Carmustine—lymphatic system cancer	0.000355	0.00232	CcSEcCtD
Dipyridamole—Oedema—Bleomycin—lymphatic system cancer	0.000354	0.00231	CcSEcCtD
Dipyridamole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000354	0.00231	CcSEcCtD
Dipyridamole—Anaemia—Carmustine—lymphatic system cancer	0.00035	0.00229	CcSEcCtD
Dipyridamole—Back pain—Vincristine—lymphatic system cancer	0.000349	0.00229	CcSEcCtD
Dipyridamole—Vomiting—Teniposide—lymphatic system cancer	0.000349	0.00228	CcSEcCtD
Dipyridamole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000346	0.00227	CcSEcCtD
Dipyridamole—Asthenia—Fludarabine—lymphatic system cancer	0.000346	0.00226	CcSEcCtD
Dipyridamole—Rash—Teniposide—lymphatic system cancer	0.000346	0.00226	CcSEcCtD
Dipyridamole—Dermatitis—Teniposide—lymphatic system cancer	0.000346	0.00226	CcSEcCtD
Dipyridamole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000345	0.00225	CcSEcCtD
Dipyridamole—Headache—Teniposide—lymphatic system cancer	0.000344	0.00225	CcSEcCtD
Dipyridamole—Pruritus—Fludarabine—lymphatic system cancer	0.000341	0.00223	CcSEcCtD
Dipyridamole—Back pain—Mitoxantrone—lymphatic system cancer	0.00034	0.00223	CcSEcCtD
Dipyridamole—Anaemia—Vincristine—lymphatic system cancer	0.000334	0.00218	CcSEcCtD
Dipyridamole—Hypotension—Bleomycin—lymphatic system cancer	0.000331	0.00216	CcSEcCtD
Dipyridamole—Diarrhoea—Fludarabine—lymphatic system cancer	0.00033	0.00216	CcSEcCtD
Dipyridamole—Convulsion—Carmustine—lymphatic system cancer	0.000328	0.00214	CcSEcCtD
Dipyridamole—Hypertension—Carmustine—lymphatic system cancer	0.000327	0.00214	CcSEcCtD
Dipyridamole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000326	0.00214	CcSEcCtD
Dipyridamole—Nausea—Teniposide—lymphatic system cancer	0.000326	0.00213	CcSEcCtD
Dipyridamole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000325	0.00213	CcSEcCtD
Dipyridamole—Vertigo—Vincristine—lymphatic system cancer	0.000325	0.00212	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000322	0.00211	CcSEcCtD
Dipyridamole—Chest pain—Carmustine—lymphatic system cancer	0.000322	0.00211	CcSEcCtD
Dipyridamole—Myalgia—Carmustine—lymphatic system cancer	0.000322	0.00211	CcSEcCtD
Dipyridamole—Anxiety—Carmustine—lymphatic system cancer	0.000321	0.0021	CcSEcCtD
Dipyridamole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000318	0.00208	CcSEcCtD
Dipyridamole—Malaise—Mitoxantrone—lymphatic system cancer	0.000317	0.00208	CcSEcCtD
Dipyridamole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000315	0.00206	CcSEcCtD
Dipyridamole—Convulsion—Vincristine—lymphatic system cancer	0.000313	0.00205	CcSEcCtD
Dipyridamole—Hypertension—Vincristine—lymphatic system cancer	0.000312	0.00204	CcSEcCtD
Dipyridamole—Oedema—Carmustine—lymphatic system cancer	0.000309	0.00202	CcSEcCtD
Dipyridamole—Myalgia—Vincristine—lymphatic system cancer	0.000308	0.00201	CcSEcCtD
Dipyridamole—Cough—Mitoxantrone—lymphatic system cancer	0.000307	0.00201	CcSEcCtD
Dipyridamole—Vomiting—Fludarabine—lymphatic system cancer	0.000307	0.00201	CcSEcCtD
Dipyridamole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000305	0.00199	CcSEcCtD
Dipyridamole—Rash—Fludarabine—lymphatic system cancer	0.000304	0.00199	CcSEcCtD
Dipyridamole—Dermatitis—Fludarabine—lymphatic system cancer	0.000304	0.00199	CcSEcCtD
Dipyridamole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000304	0.00199	CcSEcCtD
Dipyridamole—Pain—Bleomycin—lymphatic system cancer	0.000303	0.00198	CcSEcCtD
Dipyridamole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000302	0.00198	CcSEcCtD
Dipyridamole—Headache—Fludarabine—lymphatic system cancer	0.000302	0.00198	CcSEcCtD
Dipyridamole—Tachycardia—Carmustine—lymphatic system cancer	0.000301	0.00197	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000301	0.00197	CcSEcCtD
Dipyridamole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0003	0.00196	CcSEcCtD
Dipyridamole—Myalgia—Mitoxantrone—lymphatic system cancer	0.0003	0.00196	CcSEcCtD
Dipyridamole—Chest pain—Mitoxantrone—lymphatic system cancer	0.0003	0.00196	CcSEcCtD
Dipyridamole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000298	0.00195	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000297	0.00194	CcSEcCtD
Dipyridamole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000296	0.00194	CcSEcCtD
Dipyridamole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000295	0.00193	CcSEcCtD
Dipyridamole—Oedema—Vincristine—lymphatic system cancer	0.000295	0.00193	CcSEcCtD
Dipyridamole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000292	0.00191	CcSEcCtD
Dipyridamole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000289	0.00189	CcSEcCtD
Dipyridamole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000289	0.00189	CcSEcCtD
Dipyridamole—Hypotension—Carmustine—lymphatic system cancer	0.000289	0.00189	CcSEcCtD
Dipyridamole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000287	0.00188	CcSEcCtD
Dipyridamole—Oedema—Mitoxantrone—lymphatic system cancer	0.000287	0.00188	CcSEcCtD
Dipyridamole—Nausea—Fludarabine—lymphatic system cancer	0.000287	0.00188	CcSEcCtD
Dipyridamole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000285	0.00186	CcSEcCtD
Dipyridamole—Shock—Mitoxantrone—lymphatic system cancer	0.000282	0.00185	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000281	0.00184	CcSEcCtD
Dipyridamole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000281	0.00184	CcSEcCtD
Dipyridamole—Urticaria—Bleomycin—lymphatic system cancer	0.000281	0.00184	CcSEcCtD
Dipyridamole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00028	0.00183	CcSEcCtD
Dipyridamole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000279	0.00182	CcSEcCtD
Dipyridamole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000278	0.00182	CcSEcCtD
Dipyridamole—Paraesthesia—Carmustine—lymphatic system cancer	0.000277	0.00181	CcSEcCtD
Dipyridamole—Hypotension—Vincristine—lymphatic system cancer	0.000275	0.0018	CcSEcCtD
Dipyridamole—Dyspnoea—Carmustine—lymphatic system cancer	0.000275	0.0018	CcSEcCtD
Dipyridamole—Somnolence—Carmustine—lymphatic system cancer	0.000275	0.0018	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000269	0.00176	CcSEcCtD
Dipyridamole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000268	0.00176	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000267	0.00174	CcSEcCtD
Dipyridamole—Paraesthesia—Vincristine—lymphatic system cancer	0.000265	0.00173	CcSEcCtD
Dipyridamole—Pain—Carmustine—lymphatic system cancer	0.000264	0.00173	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000262	0.00171	CcSEcCtD
Dipyridamole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000261	0.00171	CcSEcCtD
Dipyridamole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000258	0.00169	CcSEcCtD
Dipyridamole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000256	0.00167	CcSEcCtD
Dipyridamole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000255	0.00167	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000255	0.00167	CcSEcCtD
Dipyridamole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000255	0.00166	CcSEcCtD
Dipyridamole—Fatigue—Vincristine—lymphatic system cancer	0.000254	0.00166	CcSEcCtD
Dipyridamole—Asthenia—Bleomycin—lymphatic system cancer	0.000254	0.00166	CcSEcCtD
Dipyridamole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000253	0.00165	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000253	0.00165	CcSEcCtD
Dipyridamole—Pain—Vincristine—lymphatic system cancer	0.000252	0.00165	CcSEcCtD
Dipyridamole—Pruritus—Bleomycin—lymphatic system cancer	0.00025	0.00164	CcSEcCtD
Dipyridamole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000248	0.00162	CcSEcCtD
Dipyridamole—Pain—Mitoxantrone—lymphatic system cancer	0.000246	0.00161	CcSEcCtD
Dipyridamole—Abdominal pain—Carmustine—lymphatic system cancer	0.000244	0.0016	CcSEcCtD
Dipyridamole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000241	0.00158	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000241	0.00158	CcSEcCtD
Dipyridamole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000237	0.00155	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000235	0.00154	CcSEcCtD
Dipyridamole—Abdominal pain—Vincristine—lymphatic system cancer	0.000233	0.00152	CcSEcCtD
Dipyridamole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000228	0.00149	CcSEcCtD
Dipyridamole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000228	0.00149	CcSEcCtD
Dipyridamole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000227	0.00148	CcSEcCtD
Dipyridamole—Vomiting—Bleomycin—lymphatic system cancer	0.000225	0.00147	CcSEcCtD
Dipyridamole—Rash—Bleomycin—lymphatic system cancer	0.000223	0.00146	CcSEcCtD
Dipyridamole—Dermatitis—Bleomycin—lymphatic system cancer	0.000223	0.00146	CcSEcCtD
Dipyridamole—Asthenia—Carmustine—lymphatic system cancer	0.000222	0.00145	CcSEcCtD
Dipyridamole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000217	0.00142	CcSEcCtD
Dipyridamole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000212	0.00138	CcSEcCtD
Dipyridamole—Asthenia—Vincristine—lymphatic system cancer	0.000212	0.00138	CcSEcCtD
Dipyridamole—Diarrhoea—Carmustine—lymphatic system cancer	0.000211	0.00138	CcSEcCtD
Dipyridamole—Nausea—Bleomycin—lymphatic system cancer	0.00021	0.00137	CcSEcCtD
Dipyridamole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000206	0.00135	CcSEcCtD
Dipyridamole—Dizziness—Carmustine—lymphatic system cancer	0.000204	0.00134	CcSEcCtD
Dipyridamole—Haemoglobin—Methotrexate—lymphatic system cancer	0.000202	0.00132	CcSEcCtD
Dipyridamole—Diarrhoea—Vincristine—lymphatic system cancer	0.000202	0.00132	CcSEcCtD
Dipyridamole—Hepatitis—Methotrexate—lymphatic system cancer	0.000201	0.00132	CcSEcCtD
Dipyridamole—Haemorrhage—Methotrexate—lymphatic system cancer	0.000201	0.00132	CcSEcCtD
Dipyridamole—Pharyngitis—Methotrexate—lymphatic system cancer	0.0002	0.00131	CcSEcCtD
Dipyridamole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000196	0.00129	CcSEcCtD
Dipyridamole—Vomiting—Carmustine—lymphatic system cancer	0.000196	0.00128	CcSEcCtD
Dipyridamole—Dizziness—Vincristine—lymphatic system cancer	0.000195	0.00128	CcSEcCtD
Dipyridamole—Rash—Carmustine—lymphatic system cancer	0.000195	0.00127	CcSEcCtD
Dipyridamole—Dermatitis—Carmustine—lymphatic system cancer	0.000195	0.00127	CcSEcCtD
Dipyridamole—Headache—Carmustine—lymphatic system cancer	0.000193	0.00127	CcSEcCtD
Dipyridamole—Tinnitus—Methotrexate—lymphatic system cancer	0.000188	0.00123	CcSEcCtD
Dipyridamole—Vomiting—Vincristine—lymphatic system cancer	0.000187	0.00123	CcSEcCtD
Dipyridamole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000187	0.00122	CcSEcCtD
Dipyridamole—Rash—Vincristine—lymphatic system cancer	0.000186	0.00122	CcSEcCtD
Dipyridamole—Dermatitis—Vincristine—lymphatic system cancer	0.000186	0.00121	CcSEcCtD
Dipyridamole—Headache—Vincristine—lymphatic system cancer	0.000185	0.00121	CcSEcCtD
Dipyridamole—Nausea—Carmustine—lymphatic system cancer	0.000183	0.0012	CcSEcCtD
Dipyridamole—Angiopathy—Methotrexate—lymphatic system cancer	0.000183	0.0012	CcSEcCtD
Dipyridamole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000183	0.00119	CcSEcCtD
Dipyridamole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000182	0.00119	CcSEcCtD
Dipyridamole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000181	0.00119	CcSEcCtD
Dipyridamole—Rash—Mitoxantrone—lymphatic system cancer	0.000181	0.00118	CcSEcCtD
Dipyridamole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000181	0.00118	CcSEcCtD
Dipyridamole—Chills—Methotrexate—lymphatic system cancer	0.000181	0.00118	CcSEcCtD
Dipyridamole—Headache—Mitoxantrone—lymphatic system cancer	0.00018	0.00118	CcSEcCtD
Dipyridamole—Alopecia—Methotrexate—lymphatic system cancer	0.000178	0.00116	CcSEcCtD
Dipyridamole—Nausea—Vincristine—lymphatic system cancer	0.000175	0.00115	CcSEcCtD
Dipyridamole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000172	0.00112	CcSEcCtD
Dipyridamole—Nausea—Mitoxantrone—lymphatic system cancer	0.000171	0.00112	CcSEcCtD
Dipyridamole—Back pain—Methotrexate—lymphatic system cancer	0.00017	0.00111	CcSEcCtD
Dipyridamole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000163	0.00106	CcSEcCtD
Dipyridamole—Anaemia—Methotrexate—lymphatic system cancer	0.000162	0.00106	CcSEcCtD
Dipyridamole—Malaise—Methotrexate—lymphatic system cancer	0.000158	0.00103	CcSEcCtD
Dipyridamole—Vertigo—Methotrexate—lymphatic system cancer	0.000157	0.00103	CcSEcCtD
Dipyridamole—Cough—Methotrexate—lymphatic system cancer	0.000153	0.001	CcSEcCtD
Dipyridamole—Convulsion—Methotrexate—lymphatic system cancer	0.000152	0.000993	CcSEcCtD
Dipyridamole—Arthralgia—Methotrexate—lymphatic system cancer	0.000149	0.000976	CcSEcCtD
Dipyridamole—Chest pain—Methotrexate—lymphatic system cancer	0.000149	0.000976	CcSEcCtD
Dipyridamole—Myalgia—Methotrexate—lymphatic system cancer	0.000149	0.000976	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000148	0.000969	CcSEcCtD
Dipyridamole—Discomfort—Methotrexate—lymphatic system cancer	0.000147	0.000964	CcSEcCtD
Dipyridamole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000143	0.000936	CcSEcCtD
Dipyridamole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00014	0.000918	CcSEcCtD
Dipyridamole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00014	0.000916	CcSEcCtD
Dipyridamole—Skin disorder—Methotrexate—lymphatic system cancer	0.000139	0.000909	CcSEcCtD
Dipyridamole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000138	0.000905	CcSEcCtD
Dipyridamole—Hypotension—Methotrexate—lymphatic system cancer	0.000134	0.000874	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00013	0.000853	CcSEcCtD
Dipyridamole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000128	0.00084	CcSEcCtD
Dipyridamole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000128	0.000834	CcSEcCtD
Dipyridamole—Somnolence—Methotrexate—lymphatic system cancer	0.000127	0.000832	CcSEcCtD
Dipyridamole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000126	0.000824	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000124	0.000808	CcSEcCtD
Dipyridamole—Fatigue—Methotrexate—lymphatic system cancer	0.000123	0.000807	CcSEcCtD
Dipyridamole—Pain—Methotrexate—lymphatic system cancer	0.000122	0.0008	CcSEcCtD
Dipyridamole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000118	0.000771	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000117	0.000765	CcSEcCtD
Dipyridamole—Urticaria—Methotrexate—lymphatic system cancer	0.000114	0.000743	CcSEcCtD
Dipyridamole—Abdominal pain—Methotrexate—lymphatic system cancer	0.000113	0.00074	CcSEcCtD
Dipyridamole—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000105	0.000689	CcSEcCtD
Dipyridamole—Asthenia—Methotrexate—lymphatic system cancer	0.000103	0.000671	CcSEcCtD
Dipyridamole—Pruritus—Methotrexate—lymphatic system cancer	0.000101	0.000662	CcSEcCtD
Dipyridamole—Diarrhoea—Methotrexate—lymphatic system cancer	9.79e-05	0.00064	CcSEcCtD
Dipyridamole—Dizziness—Methotrexate—lymphatic system cancer	9.46e-05	0.000619	CcSEcCtD
Dipyridamole—Vomiting—Methotrexate—lymphatic system cancer	9.1e-05	0.000595	CcSEcCtD
Dipyridamole—Rash—Methotrexate—lymphatic system cancer	9.02e-05	0.00059	CcSEcCtD
Dipyridamole—Dermatitis—Methotrexate—lymphatic system cancer	9.01e-05	0.000589	CcSEcCtD
Dipyridamole—Headache—Methotrexate—lymphatic system cancer	8.96e-05	0.000586	CcSEcCtD
Dipyridamole—Nausea—Methotrexate—lymphatic system cancer	8.5e-05	0.000556	CcSEcCtD
